Lead Sponsor

Hoffmann-La Roche

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

•Ability to comply with the study protocol, in the investigator's judgment
•Participation in Study GA39688 or GA39855, including completion of endoscopy and other assessments at Week 24, without discontinuation of study drug
•Completion of eDiary daily assessments for at least 4 out of 7 days in the week prior to the Week 24 visit of Study GA39688 or GA39855
•For women of childbearing potential: agreement to remain abstinent or use acceptable contraceptive methods during the treatment period and for 60 days after the last dose of study drug

•Anaphylaxis/hypersensitivity related to study drug in Study GA39688 or GA39855
•Serious adverse events related to study drug in Study GA39688 or GA39855 that the investigator or Sponsor determines may jeopardize the patient's safety if he or she continues in the study
•Uncontrolled epistaxis within Study GA39688 or GA39855
•Pregnant or breastfeeding, or intending to become pregnant during the study or within 60 days after the last dose of omalizumab
•Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study